Angiosoma Stock Current Valuation
| GSTC Stock | USD 0.0009 0.0001 12.50% |
Valuation analysis of AngioSoma helps investors to measure AngioSoma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that AngioSoma's price fluctuation is out of control at this time. Calculation of the real value of AngioSoma is based on 3 months time horizon. Increasing AngioSoma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for AngioSoma is useful when determining the fair value of the AngioSoma pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of AngioSoma. Since AngioSoma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AngioSoma Pink Sheet. However, AngioSoma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.0E-4 | Real 8.64E-4 | Hype 9.51E-4 |
The real value of AngioSoma Pink Sheet, also known as its intrinsic value, is the underlying worth of AngioSoma Company, which is reflected in its stock price. It is based on AngioSoma's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of AngioSoma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AngioSoma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AngioSoma helps investors to forecast how AngioSoma pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AngioSoma more accurately as focusing exclusively on AngioSoma's fundamentals will not take into account other important factors: AngioSoma Company Current Valuation Analysis
AngioSoma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AngioSoma Current Valuation | 9.39 M |
Most of AngioSoma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AngioSoma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AngioSoma has a Current Valuation of 9.39 M. This is 99.93% lower than that of the sector and 99.8% lower than that of the Current Valuation industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
AngioSoma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AngioSoma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of AngioSoma could also be used in its relative valuation, which is a method of valuing AngioSoma by comparing valuation metrics of similar companies.AngioSoma is currently under evaluation in current valuation category among related companies.
AngioSoma Fundamentals
| Return On Asset | -44.28 | |||
| Current Valuation | 9.39 M | |||
| Shares Outstanding | 770.36 M | |||
| Shares Owned By Insiders | 10.02 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Sales | 78,201 X | |||
| Gross Profit | (2.41 K) | |||
| EBITDA | (1.21 M) | |||
| Net Income | (1.49 M) | |||
| Cash And Equivalents | 12 | |||
| Total Debt | 20 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (327 K) | |||
| Earnings Per Share | (0.02) X | |||
| Price To Earnings To Growth | (0.08) X | |||
| Beta | 1.17 | |||
| Market Capitalization | 8.47 M | |||
| Total Asset | 9 | |||
| Net Asset | 9 |
About AngioSoma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AngioSoma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AngioSoma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AngioSoma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in AngioSoma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for AngioSoma Pink Sheet analysis
When running AngioSoma's price analysis, check to measure AngioSoma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioSoma is operating at the current time. Most of AngioSoma's value examination focuses on studying past and present price action to predict the probability of AngioSoma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioSoma's price. Additionally, you may evaluate how the addition of AngioSoma to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |